Wells Fargo lowered the firm’s price target on Cabaletta Bio to $34 from $35 and keeps an Overweight rating on the shares. The firm is “disappointed” there won’t be a more robust update for CABA-201 in the first half of 2024, but thinks this is largely priced in given the recent weakness, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Receives Orphan Drug Status for CABA-201
- Cabaletta Bio granted Orphan Drug designation to CABA-201
- Cabaletta Bio treatment of systemic sclerosis granted orphan designation
- Cabaletta Bio, Inc. (CABA) Q4 Earnings Cheat Sheet